Finding the right dose of fulvestrant in breast cancer

Cancer Treatment Reviews

Volumn 39, Issue 2, 2013, Pages 136-141

  Estevez L ^a   Alvarez, I ^b   Tusquets, I ^c   Segui M A ^d   Munoz M ^e   Fernandez Y ^f   Lluch, A ^g  

^a Centro Integral Oncologico Clara Campal   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d Medical Oncology Department   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f Hospital de Oviedo   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

0020; 0021; 0025; 500mg dosage; Breast cancer; CONFIRM; EFECT; FINDER 1; FINDER 2; FIRST; Fulvestrant; NEWEST

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; FULVESTRANT; PROGESTERONE RECEPTOR;

AREA UNDER THE CURVE; BONE TURNOVER; BREAST CANCER; CANCER HORMONE THERAPY; CANCER STAGING; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FEMALE; HUMANS;

EID: 84869509791     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.06.003     Document Type: Review

References (19)

1. McKeage K., Curran M.P., Plosker G.L. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Drugs 2004, 64:633-648.
2. Wakeling A.E., Dukes M., Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991, 51:3867-3873.
3. Addo S., Yates R.A., Laight A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br J Cancer 2002, 87:1354-1359.
4. Robertson J.F., Nicholson R.I., Bundred N.J., et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001, 61:6739-6746.
5. Croxtall J.D., McKeage K. Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women. Drugs 2011, 71:363-380.
6. Howell A., Robertson J.F.R., Quaresma Albano J., et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002, 20:3396-3403.
7. Osborne C.K., Pippen J., Jones S.E., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progression on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002, 15:3386-3395.
8. Xu B., Jiang Z., Shao Z., et al. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of multicentre, double-blind, randomised phase III trial. Cancer Chemother Pharmacol 2011, 67:223-230.
9. Chia S., Gradishar W., Mauriac L., et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with EXE after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results form EFECT. J Clin Oncol 2008, 26:1664-1670.
10. Howell A., Robertson J.F., Abram P., et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004, 22:1605-1613.
11. Di Leo A., Jerusalem G., Petruzelka L., et al. Results of the CONFIRM phase III trial comparing fulvestrant 250mg with fulvestrant 500mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010, 28:4594-4600.
12. Robertson J.F., Llombart-Cussac A., Rolski J., et al. Activity of fulvestrant 500mg versus anastrozole 1mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009, 27:4530-4535.
13. Kuter I., Hegg R., Singer C.F., Badwe R., et al. Fulvestrant 500mg vs 250mg: first results from NEWEST, a randomized, phase II neoadjuvant trial in postmenopausal women with locally advanced, estrogen receptor-positive breast cancer. Breast Cancer Res Treat 2008, 109:589.
14. Ohno S., Rai Y., Iwata H., et al. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER 1). Ann Oncol 2010, 21:2342-2347.
15. Pritchard K.I., Rolski J., Papai Z., et al. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER 2). Breast Cancer Res Treat 2010, 123:453-461.
16. Yerushalmi R., Woods R., Ravdin P.M., Hayes M.M., Gelmon K.A. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010, 11:174-183.
17. Robertson J.F.R., Lindemann J.P.O., Llombart-Cussac A., et al. A comparison of fulvestrant 500mg with anastrozole as first-line treatment for advanced breast cancer: follow-up analysis from the FIRST study. 33rd SABCS 2010, S1-3. Abstract.
18. Bonneterre J., Buzdar A., Nabholtz J.M., et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001, 92:2247-2258.
19. Mouridsen H., Gershanovich M., Sun Y., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001, 19:2596-2606.